Comparison of the Effectiveness of Rifaximin plus Lactulose versus Lactulose Alone in Overt Hepatic Encephalopathy in Terms of Complete Reversal
DOI:
https://doi.org/10.37018/JFJMU/5421Keywords:
Overt Hepatic Encephalopathy, Rifaximin, Lactulose, Reversal of OHE, Model for End-Stage Liver Disease (MELD)Abstract
Background: Hepatic encephalopathy is a serious complication of liver disease, marked by cognitive impairment and potentially life-threatening consequences. Lactulose has long been a standard treatment, but its effectiveness may be limited. Adding rifaximin to lactulose has shown promising results in managing overt hepatic encephalopathy (OHE). This study compared the frequency of complete reversal of encephalopathy by rifaximin plus lactulose versus lactulose alone in patients with OHE.
Patients and methods: A randomized controlled trial was carried out at Gastroenterology, DHQ, Gujranwala. The patients diagnosed with hepatic encephalopathy (age range = 18-60 years) were included. On the contrary, patients with serum creatinine of >1.5 mg/dl at admission, diagnosed with hepatocellular carcinoma, active alcohol intake (<4 weeks) and patients with significant comorbidities like CVA, epilepsy, and dementia were excluded from the study were not included in the study. Ninety patients into two equal groups; Group A-B. A patients received a combination therapy of Rifaximin (550mg tablet twice daily) and lactulose (30-60 ml thrice a day). Group B patients received lactulose (30-60 ml thrice times daily) placebo capsule (sugar) thrice daily. Both groups were monitored for achievement of optimal bowel function (two to three semisoft stools per day).
Results: The patients was 44.9 years. Overall there were 66 (73.3%) males 24 (26.7%) females. The mean MELD scores in group A-B were 33.76 ± 16.76 and 34.36 ± 15.85. The mean duration of liver cirrhosis in group A and group B was 6.49 ± 2.25 and 6.67 ± 2.40, respectively. In group A, a complete reversal of HE was seen in 38 (84.4%) cases while in group B the complete reversal of HE was observed in 24 (53.3%) cases (p-value <0.05).
Conclusion: The combination of Rifaximin with lactulose is more effective in treating overt hepatic encephalopathy compared to lactulose alone in terms of complete reversal.
Downloads
Published
How to Cite
Issue
Section
License
The Journal of Fatima Jinnah Medical University follows the Attribution Creative Commons-Non commercial (CC BY-NC) license which allows the users to copy and redistribute the material in any medium or format, remix, transform and build upon the material. The users must give credit to the source and indicate, provide a link to the license, and indicate if changes were made. However, the CC By-NC license restricts the use of material for commercial purposes. For further details about the license please check the Creative Commons website. The editorial board of JFJMU strives hard for the authenticity and accuracy of the material published in the journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board.
